Rodrigues Matthew J, Cabry Marc, Collie Gavin, Carter Michael, McAndrew Craig, Owen Robin L, Bellenie Benjamin R, Le Bihan Yann-Vaï, van Montfort Rob L M
Centre for Cancer Drug Discovery The Institute of Cancer Research 15 Cotswold Road Sutton LondonSM2 5NG United Kingdom.
Division of Structural Biology The Institute of Cancer Research LondonSW3 6JB United Kingdom.
J Appl Crystallogr. 2024 Nov 26;57(Pt 6):1951-1965. doi: 10.1107/S1600576724010549. eCollection 2024 Dec 1.
Protein-inhibitor crystal structures aid medicinal chemists in efficiently improving the potency and selectivity of small-molecule inhibitors. It is estimated that a quarter of lead molecules in drug discovery projects are halogenated. Protein-inhibitor crystal structures have shed light on the role of halogen atoms in ligand binding. They form halogen bonds with protein atoms and improve shape complementarity of inhibitors with protein binding sites. However, specific radiation damage (SRD) can cause cleavage of carbon-halogen (C-) bonds during X-ray diffraction data collection. This study shows significant C- bond cleavage in protein-ligand structures of the therapeutic cancer targets B-cell lymphoma 6 (BCL6) and heat shock protein 72 (HSP72) complexed with halogenated ligands, which is dependent on the type of halogen and chemical structure of the ligand. The study found that metrics used to evaluate the fit of the ligand to the electron density deteriorated with increasing X-ray dose, and that SRD eliminated the anomalous signal from brominated ligands. A point of diminishing returns is identified, where collecting highly redundant data reduces the anomalous signal that may be used to identify binding sites of low-affinity ligands or for experimental phasing. Straightforward steps are proposed to mitigate the effects of C- bond cleavage on structures of proteins bound to halogenated ligands and to improve the success of anomalous scattering experiments.
蛋白质-抑制剂晶体结构有助于药物化学家有效提高小分子抑制剂的效力和选择性。据估计,药物研发项目中四分之一的先导分子是卤代的。蛋白质-抑制剂晶体结构揭示了卤素原子在配体结合中的作用。它们与蛋白质原子形成卤键,并改善抑制剂与蛋白质结合位点的形状互补性。然而,特定辐射损伤(SRD)会在X射线衍射数据收集过程中导致碳-卤(C-)键断裂。本研究表明,与卤代配体复合的治疗性癌症靶点B细胞淋巴瘤6(BCL6)和热休克蛋白72(HSP72)的蛋白质-配体结构中存在显著的C-键断裂,这取决于卤素类型和配体的化学结构。研究发现,用于评估配体与电子密度拟合度的指标会随着X射线剂量的增加而恶化,并且SRD会消除溴代配体的反常信号。确定了一个收益递减点,即收集高度冗余的数据会减少可用于识别低亲和力配体结合位点或用于实验相位分析的反常信号。本文提出了一些简单的步骤,以减轻C-键断裂对与卤代配体结合的蛋白质结构的影响,并提高反常散射实验的成功率。